American Capital Advisory LLC Has $735,000 Holdings in Sanofi (NASDAQ:SNY)

American Capital Advisory LLC lowered its position in Sanofi (NASDAQ:SNY) by 34.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 15,247 shares of the company’s stock after selling 8,134 shares during the period. American Capital Advisory LLC’s holdings in Sanofi were worth $735,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at about $344,000. The Manufacturers Life Insurance Company lifted its stake in Sanofi by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock valued at $1,530,000 after buying an additional 6,756 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Sanofi by 3.8% during the 3rd quarter. SG Americas Securities LLC now owns 15,068 shares of the company’s stock worth $868,000 after buying an additional 548 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Sanofi by 51.2% during the 3rd quarter. GAMMA Investing LLC now owns 4,632 shares of the company’s stock worth $267,000 after buying an additional 1,569 shares during the period. Finally, Hexagon Capital Partners LLC increased its stake in shares of Sanofi by 5.0% in the 3rd quarter. Hexagon Capital Partners LLC now owns 5,356 shares of the company’s stock valued at $309,000 after acquiring an additional 255 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on SNY. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $53.35 on Friday. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. The stock has a market cap of $135.39 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The stock’s fifty day simple moving average is $49.72 and its two-hundred day simple moving average is $52.37.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.